Abstract
The mineralocorticoid receptor (MR) acts as an essential regulator of blood pressure, volume status, and electrolyte balance. However, in recent decades, a growing body of evidence has suggested that MR may also have a role in mediating pro-inflammatory, pro-oxidative, and pro-fibrotic changes in several target organs, including the adipose tissue. The finding that MR is overexpressed in the adipose tissue of patients with obesity has led to the hypothesis that this receptor can contribute to adipokine dysregulation and low-grade chronic inflammation, alterations that are linked to the development of obesity-related metabolic and cardiovascular complications. Moreover, several studies in animal models have investigated the role of MR antagonists (MRAs) in preventing the metabolic alterations observed in obesity. In the present review we will focus on the potential mechanisms by which MR activation can contribute to adipose tissue dysfunction in obesity and on the possible beneficial effects of MRAs in this setting.
Subject
Food Science,Nutrition and Dietetics
Reference101 articles.
1. WHO (2000). Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation. World Health Organ. Technol Rep. Ser., 894.
2. Obesity as a Disease: The Obesity Society 2018 Position Statement;Obesity,2018
3. The medical care costs of obesity: An instrumental variables approach;J. Health Econ.,2012
4. Direct medical costs of obesity in the United States and the most populous states;J. Manag. Care Spéc. Pharm.,2021
5. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants;Lancet,2011
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献